We have been pioneering innovation in sleep medicine for over 20 years, with the priorities of those living with hard-to-treat conditions embedded into our drug development process from early drug discovery stages through commercialization and beyond.
We put the priorities of patients first throughout our research and our Phase 4 studies in narcolepsy and idiopathic hypersomnia exemplify how this approach is pushing our understanding of sleep conditions further. By centering the voices of those living with sleep conditions in our trial designs we ensure our studies evaluate symptoms that have a meaningful impact on their lives. Engaging with trial participants and listening to their needs may boost trial retention and validate their experiences – which is important for a community whose symptoms are often misunderstood.
Input from people living with sleep conditions directly influences how we design our trials and the outcomes we measure. Their insights not only help us determine measurable outcomes but also help optimize the study design to prioritize participants’ well-being throughout the study process.
As part of our long-standing commitment to people living with sleep disorders, we will continue to develop and use innovative clinical trial techniques to understand their experiences so that we can empower them to embrace a healthier future. Read more here.
